Oral Bacteria May Diagnose Pancreatic Cancer
|
By LabMedica International staff writers Posted on 04 Jun 2014 |
|
Image: The anaerobic bacteria Leptotrichia species, Gram-stain from blood culture (Photo courtesy of Mike Dyall-Smith).
Patients with pancreatic cancer have a different and distinct profile of specific bacteria in their saliva compared to healthy controls and even patients with other cancers or pancreatic diseases.
Patients diagnosed in the early stages of pancreatic cancer have a 5-year survival rate of 21.5%, but unfortunately symptoms do not appear until after the cancer has become untreatable in the vast majority of cases.
Scientists from San Diego State University (CA, USA) compared the diversity of saliva bacteria across 131 patients, 63 females and 68 males, being treated at the University of California, San Diego (UCSD) Moores Cancer Center (La Jolla, CA, USA). Of these patients, 14 had been diagnosed with pancreatic cancer, 13 with pancreatic disease, 22 with other forms of cancer, and 10 were disease free.
The results of the study found that patients diagnosed with pancreatic cancer had higher levels of two particular oral bacteria, Leptotrichia and Campylobacter, when compared to any other healthy or diseased state including noncancerous pancreatic disease. Those with pancreatic cancer also had lower levels of Streptococcus, Treponema, and Veillonella. These findings could form the basis for a test to diagnose the pancreatic cancer in its early stages.
Pedro Torres, BS, the coauthor of the study with Scott T. Kelley, PhD, said, “Our studies suggest that ratios of particular types of bacteria found in saliva may be indicative of pancreatic cancer. The results also suggest the presence of a consistently distinct microbial profile for pancreatic cancer. We may be able to detect pancreatic cancer at its early stages by taking individuals’ saliva and looking at the ratios of these bacteria.”
In the USA, approximately 40,000 people die every year due to pancreatic adenocarcinoma, making it the fourth leading cause of cancer related death. The study was presented on May 18, 2014, at the Annual meeting of the American Society for Microbiology held May 17–20, 2014, in Boston (MA, USA).
Related Links:
San Diego State University
Moores Cancer Center
Patients diagnosed in the early stages of pancreatic cancer have a 5-year survival rate of 21.5%, but unfortunately symptoms do not appear until after the cancer has become untreatable in the vast majority of cases.
Scientists from San Diego State University (CA, USA) compared the diversity of saliva bacteria across 131 patients, 63 females and 68 males, being treated at the University of California, San Diego (UCSD) Moores Cancer Center (La Jolla, CA, USA). Of these patients, 14 had been diagnosed with pancreatic cancer, 13 with pancreatic disease, 22 with other forms of cancer, and 10 were disease free.
The results of the study found that patients diagnosed with pancreatic cancer had higher levels of two particular oral bacteria, Leptotrichia and Campylobacter, when compared to any other healthy or diseased state including noncancerous pancreatic disease. Those with pancreatic cancer also had lower levels of Streptococcus, Treponema, and Veillonella. These findings could form the basis for a test to diagnose the pancreatic cancer in its early stages.
Pedro Torres, BS, the coauthor of the study with Scott T. Kelley, PhD, said, “Our studies suggest that ratios of particular types of bacteria found in saliva may be indicative of pancreatic cancer. The results also suggest the presence of a consistently distinct microbial profile for pancreatic cancer. We may be able to detect pancreatic cancer at its early stages by taking individuals’ saliva and looking at the ratios of these bacteria.”
In the USA, approximately 40,000 people die every year due to pancreatic adenocarcinoma, making it the fourth leading cause of cancer related death. The study was presented on May 18, 2014, at the Annual meeting of the American Society for Microbiology held May 17–20, 2014, in Boston (MA, USA).
Related Links:
San Diego State University
Moores Cancer Center
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Platelet Function Analyzer
PL-12
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Latest Pathology News
- Roche Launches Automated Test to Support Mesothelioma Differential Diagnosis
- AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
- Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer
- AI Pathology Tool Predicts DNA Repair Deficiency in High-Grade Serous Ovarian Cancer
- AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps
- AI Pre-Screening Helps Identify Lung Cancer Cases for Additional Biomarker Testing
- AI Pathology Platform Targets Workflow Delays and Molecular Test Failures
- Updated Digital Pathology Platform Expands AI Integration for Cancer Diagnosis
- Molecular Testing Refines Barrett’s Esophagus Progression Risk Beyond Biopsy Findings
- AI Histopathology Tool Distinguishes Ewing Sarcoma for Diagnosis
- Rapid Mass Spectrometry Test May Aid Glioma Margin Decisions
- Genomic Classifier Predicts Benefit From Adding Hormone Therapy to Salvage Prostate Radiation
- Multimodal AI Supports Prostate Cancer Risk Assessment Across Diverse Cohorts
- New AI Model Maps Where Glioblastoma Could Return After Surgery
- Simple Test Could Reduce the Need for Invasive Uterine Cancer Checks
- Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival
Channels
Clinical Chemistry
view channel
Blood Proteins Linked to Mortality Risk and Biological Aging Across Organ Systems
Older adults of the same chronological age can differ markedly in health, chronic disease burden, and resilience. Biological age aims to capture these differences by reflecting how rapidly the body and... Read more
Two-Step Blood Test Improves Specificity for Alzheimer’s Diagnosis
Early Alzheimer’s disease can be difficult to identify before more severe cognitive symptoms emerge. Blood tests measuring phosphorylated tau protein p-tau217 may help detect disease-related changes, but... Read more
Molecular Diagnostics
view channel
Tumor and Immune Biomarkers Linked to Treatment Response in T-Cell Lymphoma
T-follicular helper cell lymphoma (TFHL) is a subtype of peripheral T-cell lymphoma associated with poor prognosis and limited treatment options after relapse. Its molecular abnormalities include frequent... Read more
Blood MRD Testing Aids Risk Analysis in Bladder and Other Cancers
Natera (Austin, TX, USA) presented findings from 25 abstracts, including nine oral presentations, at the ESMO Congress 2026 in Madrid. The research examined circulating tumor DNA (ctDNA) testing for molecular... Read more
Hematology
view channel
Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification
Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more
New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL
Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read more
Immunology
view channel
Prototype Point-of-Care Lateral Flow Test Aims to Improve Neonatal Sepsis Triage
Sepsis in newborns and young infants remains a major clinical challenge, particularly in low- and middle-income countries. An estimated 2.3 million newborns die each year, with sepsis contributing substantially... Read more
Immune and Inflammatory Markers May Help Assess CAR T-Cell Complication Risk
Cytokine release syndrome (CRS) can occur after chimeric antigen receptor (CAR) T-cell therapy in patients with autoimmune disease. Identifying which patients are more likely to develop this complication... Read more
Pathology
view channel
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Roche Launches Automated Test to Support Mesothelioma Differential Diagnosis
Mesothelioma is a rare, deadly cancer that forms in the tissue lining many internal organs. Most patients are diagnosed late, with median overall survival reported at 12 to 18 months. Differential diagnosis... Read more
Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer
In hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer, accurate recurrence-risk assessment helps guide treatment decisions. However, individual risks... Read more
AI Pathology Tool Predicts DNA Repair Deficiency in High-Grade Serous Ovarian Cancer
High-grade serous tubo-ovarian carcinoma is an aggressive cancer arising in the ovaries or fallopian tubes. Some tumors exhibit homologous recombination deficiency (HRD), a feature reflecting impaired DNA repair.... Read moreTechnology
view channel
Microfluidic Assay Predicts Treatment Response in Pediatric Leukemia
Acute lymphoblastic leukemia (ALL) is a rapidly developing blood cancer that can disrupt production of mature infection-fighting white blood cells within months. More than 120,000 people in the U.... Read more
AI Models Use Routine Blood Tests and Health Records to Predict Cancer Risk
Cancer screening programs cover only certain cancers and often rely on broad eligibility criteria, limiting individualized risk assessment across multiple cancer types. Routine health data, including blood... Read more
Industry
view channel
CE-Marked IVD Sequencing Platform Launches Across Ten EU Countries
Clinical laboratories using sequencing in regulated diagnostic workflows need systems that support clearly defined processes and documentation. In Europe, meeting applicable EU IVDR requirements also means... Read more
